MedTrace Logo

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

NCT01358578 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1306

Last updated 2021-01-05

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.

Conditions

  • Chronic Plaque Psoriasis

Interventions

DRUG

Placebo

Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept

DRUG

secukinumab (AIN457)

secukinumab (AIN457) 150mg or 300mg subcutaneous

DRUG

etanercept

etanercept 50mg subcutaneous

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Canada
  • Colombia
  • Egypt
  • Finland
  • France
  • Germany
  • Guatemala
  • Hungary
  • Iceland
  • India
  • Italy
  • Philippines
  • Poland
  • Romania
  • Singapore
  • South Korea
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01358578 on ClinicalTrials.gov